MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)*
Organization & Developments: Syros
Parents
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)*
Children
*It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
*Pioneering a new area of medicine focused on controlling the expression of genes
*Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases.
2018: Syros Pharmaceuticals (SYRS)_seekingalpha.com
2019: Checking In On Syros Pharmaceuticals_seekingalpha.com
2020: Syros Pharmaceuticals After The Orsenix Deal
2021: Revisiting Syros Pharmaceuticals
2022: Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
2023: Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
2024: Syros Pharmaceuticals: Rising Despite Dilution, A Must Look_ seekingalpha.com
2024: Syros stock craters after lead cancer therapy flops in Phase III trial
Jumps
*Key People: Syros
Finance & Acquisitions: Syros